Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Director Emerald Fennell explains why "Wuthering Heights" has quotation marks around the title - 2$30K Disability Scam Implodes After Surf Trip in Mexico
- 3Rick Steves' Favorite Time To Visit Spain Has Lower Prices And Fewer Crowds
- 410 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- 5Iran war drives global fertilizer prices up, raising food cost fears
- From ‘Project Hail Mary’ to Artemis II, spaceflight captures audiences when it centers on people because human space travel is hazardous
- Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II
- Exploring the Main Year of Life as a parent: Individual Encounters
- Merz says army could be involved in mine-clearing from Hormuz
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- Dominating the Art of Composing: Creator Bits of knowledge
- AstraZeneca to acquire Modella AI to speed oncology drug research
- Far-right German youth group delegates seek deportations, remigration
